PE20091163A1 - Anticuerpos para gdf8 - Google Patents

Anticuerpos para gdf8

Info

Publication number
PE20091163A1
PE20091163A1 PE2008001853A PE2008001853A PE20091163A1 PE 20091163 A1 PE20091163 A1 PE 20091163A1 PE 2008001853 A PE2008001853 A PE 2008001853A PE 2008001853 A PE2008001853 A PE 2008001853A PE 20091163 A1 PE20091163 A1 PE 20091163A1
Authority
PE
Peru
Prior art keywords
seq
amino acid
acid sequence
heavy
duty
Prior art date
Application number
PE2008001853A
Other languages
English (en)
Inventor
Edward Roland Lavallie
Lisa Anne Collins-Racie
Christopher John Corcoran
Lioudmila Gennadievna Tchistiakova
John Adam Nowak
Riyez Karim
Xiang-Yang Tan
Kimberly Ann Marquette
Geertruida Machteld Veldman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20091163A1 publication Critical patent/PE20091163A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K999/00—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K999/00—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group
    • H05K999/99—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group dummy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

REFERIDA A UN ANTAGONISTA ESPECIFICO PARA EL FACTOR 8 DE CRECIMIENTO Y DIFERENCIACION (GDF8) Y QUE NO SE UNE ESPECIFICAMENTE A BMP11, DONDE DICHO ANTAGONISTA PUEDE SER UN ANTICUERPO POLICLONAL, MONOCLONAL, MONOESPECIFICO, POLIESPECIFICO, HUMANIZADO, TETRAMERICO, TETRAVALENTE, ENTRE OTROS, QUE COMPRENDE UNA REGION DETERMINANTE DE COMPLEMENTARIEDAD (CDR) QUE COMPRENDE UNA SECUENCIA DE AMINOACIDO TAL COMO UNA SECUENCIA DE AMINOACIDO DE LA SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:26, ENTRE OTROS Y UNA CADENA PESADA QUE COMPRENDE UNA SECUENCIA DE AMINOACIDO SELECCIONADA DE UNA SECUENCIA DE AMINOACIDO SEQ ID NO:14 Y SEQ ID NO:18. TAMBIEN ESTA REFERIDA A UN VECTOR, UN POLINUCLEOTIDO, UNA CELULA ANFITRIONA Y UNA COMPOSICION FARMACEUTICA. DICHOS ANTAGONISTAS SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS DEGENERATIVOS DEL MUSCULO, OSEOS Y DE METABOLISMO DE INSULINA
PE2008001853A 2007-11-01 2008-10-30 Anticuerpos para gdf8 PE20091163A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US178307P 2007-11-01 2007-11-01

Publications (1)

Publication Number Publication Date
PE20091163A1 true PE20091163A1 (es) 2009-08-09

Family

ID=40303702

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001853A PE20091163A1 (es) 2007-11-01 2008-10-30 Anticuerpos para gdf8

Country Status (19)

Country Link
US (4) US8415459B2 (es)
EP (2) EP2215118B1 (es)
JP (1) JP5756291B2 (es)
KR (1) KR20100074321A (es)
CN (1) CN101970487A (es)
AR (1) AR069157A1 (es)
AU (1) AU2008319265A1 (es)
CA (1) CA2704315C (es)
CO (1) CO6270358A2 (es)
ES (1) ES2514518T3 (es)
IL (1) IL205448A0 (es)
MX (1) MX2010004915A (es)
PA (1) PA8802601A1 (es)
PE (1) PE20091163A1 (es)
RU (1) RU2447084C2 (es)
SA (1) SA08290697B1 (es)
TW (1) TW200934510A (es)
WO (1) WO2009058346A1 (es)
ZA (1) ZA201003876B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332977B1 (en) * 2004-07-23 2015-11-25 Acceleron Pharma Inc. ActRII receptor polypeptides
EA026874B1 (ru) 2005-11-23 2017-05-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MY162136A (en) * 2006-12-18 2017-05-31 Acceleron Pharma Inc Activin-actrii antagonists and uses for treating anemia
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
CN107050424A (zh) * 2007-02-01 2017-08-18 阿塞勒隆制药公司 活化素‑actriia拮抗剂及在治疗或预防乳腺癌中的用途
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
MX368173B (es) 2007-02-09 2019-09-23 Acceleron Pharma Inc Una composición farmacéutica que comprende una proteína de fusión actriia-fc expresada de células cho.
EP2207562B1 (en) 2007-09-18 2017-05-31 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2009158035A2 (en) * 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
ES2808139T3 (es) * 2008-08-14 2021-02-25 Acceleron Pharma Inc Trampas de GDF
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
EP2440576A4 (en) 2009-06-08 2013-11-20 Acceleron Pharma Inc PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
JP2012531582A (ja) * 2009-06-26 2012-12-10 アトラス・アンティボディーズ・アクチボラゲット 免疫検出性の改善
IN2012DN02766A (es) * 2009-09-09 2015-09-18 Acceleron Pharma Inc
ES2869864T3 (es) * 2009-11-03 2021-10-26 Acceleron Pharma Inc Procedimientos para el tratamiento de la enfermedad del hígado graso
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
WO2012012571A1 (en) 2010-07-21 2012-01-26 Hans Zassenhaus Biolayer interferometry measurement of biological targets
EP2606066A1 (en) * 2010-08-16 2013-06-26 Amgen Inc. Antibodies that bind myostatin, compositions and methods
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
CN110038135B (zh) 2011-03-17 2021-03-05 伯明翰大学 重新定向的免疫治疗
SI2780368T1 (en) 2011-11-14 2018-04-30 Regeneron Pharmaceuticals, Inc. INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
TWI717591B (zh) 2012-08-24 2021-02-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE
MY172863A (en) 2012-09-13 2019-12-13 Bristol Myers Squibb Co Fibronectin based scaffold domain proteins that bind to myostatin
EP3308796B1 (en) 2012-11-02 2021-07-14 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
EP2981822B1 (en) 2013-05-06 2020-09-02 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
EP2853898B1 (en) 2013-09-27 2017-01-04 Medizinische Hochschule Hannover Analysis of myostatin in serum
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
WO2016073906A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
CN107075518B (zh) * 2014-11-24 2021-03-09 私募蛋白质体公司 用于结合生长分化因子11的核酸化合物
PT3227675T (pt) 2014-12-03 2023-05-30 Celgene Corp Antagonistas da ativina-actrii e utilizações para tratamento da síndrome mielodisplásica
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
WO2016120647A2 (en) * 2015-01-30 2016-08-04 Debreceni Egyetem Muscle regeneration
WO2016120652A1 (en) * 2015-01-30 2016-08-04 Debreceni Egyetem Muscle differentiation
KR20170110129A (ko) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
AU2016249015B2 (en) 2015-04-15 2022-03-24 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with GDF8 inhibitors
EP3878857A1 (en) 2015-04-22 2021-09-15 Biogen MA Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
MX2018003196A (es) 2015-09-15 2019-05-16 Scholar Rock Inc Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
SI3374398T1 (sl) 2015-11-10 2020-07-31 Medimmune, Llc Vezavne molekule, specifične za ASCT2 in njihove uporabe
MY189425A (en) * 2015-12-18 2022-02-10 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3394098A4 (en) * 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
US10287345B2 (en) 2016-01-08 2019-05-14 Scholar Rock, Inc. Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
JP2019509759A (ja) * 2016-01-14 2019-04-11 ビーピーエス バイオサイエンス、インク．Ｂｐｓ Ｂｉｏｓｃｉｅｎｃｅ， Ｉｎｃ． 抗ｐｄ−１抗体及びその使用
HUE062976T2 (hu) 2016-03-11 2023-12-28 Scholar Rock Inc TGFbéta1-hez kötõdõ immunglobulinok és alkalmazásuk
HUE051480T2 (hu) 2016-06-13 2021-03-01 Scholar Rock Inc Miosztatin-inhibitorok alkalmazása és kombinációs terápiák
MX2018014375A (es) * 2016-06-17 2019-04-22 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y metodos de uso.
CA2971303A1 (en) 2016-06-21 2017-12-21 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
WO2018129329A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
JP7198757B2 (ja) 2017-01-06 2023-01-04 スカラー ロック インコーポレイテッド ミオスタチン活性化の阻害により代謝疾患を処置するための方法
JP2021515003A (ja) 2018-03-01 2021-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 体組成を変更するための方法
HUE056501T2 (hu) 2018-07-11 2022-02-28 Scholar Rock Inc Izoforma-szelektív TGF-béta1 inhibitorok és alkalmazásuk
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
WO2020014460A1 (en) 2018-07-11 2020-01-16 Scholar Rock, Inc. HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
AU2019401575A1 (en) 2018-12-18 2021-06-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, GDF8 and Activin A
EP3990030A1 (en) 2019-06-27 2022-05-04 Pfizer Inc. Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
EP4010368A4 (en) 2019-08-07 2023-09-06 Aqualung Therapeutics Corp. ANTI-NAMPT ANTIBODIES AND THEIR USES
JP2023511255A (ja) 2020-01-11 2023-03-17 スカラー ロック インコーポレイテッド ＴＧＦ－β阻害剤及びその使用
JP2023510793A (ja) 2020-01-11 2023-03-15 スカラー ロック インコーポレイテッド ＴＧＦβ阻害剤およびその使用
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2022261480A1 (en) * 2021-06-11 2022-12-15 The Regents Of The University Of California Heparan sulfate mimetics to improve glucose clearance
CN114181908B (zh) * 2021-07-23 2023-11-17 无锡傲锐东源生物科技有限公司 抗人s100b蛋白鼠单克隆抗体及其应用
WO2023168326A2 (en) * 2022-03-03 2023-09-07 The Brigham And Women´S Hospital, Inc. Humanized and affinity-matured anti-ceacam1 antibodies and methods of use
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
US11802870B1 (en) * 2022-12-13 2023-10-31 Panazee Kinetic immunoassay systems and methods

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ES2087911T3 (es) 1989-04-28 1996-08-01 Riker Laboratories Inc Dispositivo de inhalacion de polvo seco.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
CA2194660C (en) * 1994-07-08 2009-09-29 Se-Jin Lee Growth differentiation factor-11
US5562332A (en) 1994-12-27 1996-10-08 Hss Industries, Inc. Lobby table for lockable boxes with handicapped shelf
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
SE9502800D0 (sv) 1995-08-10 1995-08-10 Astra Ab Disposable inhaler
EP0869815A1 (en) 1995-09-21 1998-10-14 University Of Utah Research Foundation Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP2003517580A (ja) 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
EP1322395B1 (en) 2000-09-13 2011-02-23 Entegris, Inc. Liquid filtration device
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
WO2003014161A2 (en) 2001-08-10 2003-02-20 Aberdeen University Antigen binding domains from fish
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
BR0307907A2 (pt) * 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
AU2003216345A1 (en) 2002-02-21 2003-09-09 Wyeth Follistatin domain containing proteins
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2004245025A1 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (GDF8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
CN1934266A (zh) * 2004-03-23 2007-03-21 伊莱利利公司 抗肌肉生长抑素抗体
EA014112B1 (ru) * 2004-03-23 2010-10-29 Эли Лилли Энд Компани Моноклональное антитело к миостатину и способы его применения
KR20070084170A (ko) 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
BRPI0609439A2 (pt) 2005-03-23 2010-04-06 Wyeth Corp detecção de uma resposta imunológica a agentes moduladores de gdf-8
CA2601667A1 (en) * 2005-03-23 2006-09-28 Wyeth Detection of gdf-8 modulating agents
US7807159B2 (en) * 2005-04-25 2010-10-05 Amgen Fremont Inc. Antibodies to myostatin
PT1915397E (pt) * 2005-08-19 2015-04-30 Univ Pennsylvania Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8
KR101135220B1 (ko) * 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
WO2008030706A2 (en) * 2006-09-05 2008-03-13 Eli Lilly And Company Anti-myostatin antibodies
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US8841340B2 (en) * 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound

Also Published As

Publication number Publication date
WO2009058346A1 (en) 2009-05-07
EP2805970A2 (en) 2014-11-26
CO6270358A2 (es) 2011-04-20
ZA201003876B (en) 2011-04-28
IL205448A0 (en) 2010-12-30
EP2805970A3 (en) 2015-03-04
CA2704315A1 (en) 2009-05-07
US8415459B2 (en) 2013-04-09
EP2215118B1 (en) 2014-08-06
CA2704315C (en) 2016-05-24
MX2010004915A (es) 2010-05-27
AU2008319265A1 (en) 2009-05-07
RU2447084C2 (ru) 2012-04-10
PA8802601A1 (es) 2009-06-23
KR20100074321A (ko) 2010-07-01
RU2010117018A (ru) 2011-12-10
US20180265578A1 (en) 2018-09-20
US10189896B2 (en) 2019-01-29
AR069157A1 (es) 2009-12-30
US9850301B2 (en) 2017-12-26
TW200934510A (en) 2009-08-16
US20090148436A1 (en) 2009-06-11
US9409981B2 (en) 2016-08-09
JP2011504096A (ja) 2011-02-03
JP5756291B2 (ja) 2015-07-29
US20140023638A1 (en) 2014-01-23
SA08290697B1 (ar) 2012-02-12
US20170145084A1 (en) 2017-05-25
EP2215118A1 (en) 2010-08-11
ES2514518T3 (es) 2014-10-28
CN101970487A (zh) 2011-02-09

Similar Documents

Publication Publication Date Title
PE20091163A1 (es) Anticuerpos para gdf8
EA200970880A1 (ru) Стабильные композиции на основе антител
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
ES2657226T3 (es) Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
RU2017117596A (ru) Связывающие молекулы, специфичные в отношении CD73, и пути их применения
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
AR079336A1 (es) Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
PH12015501593A1 (en) Stable and soluble antibodies inhibiting vegf
PE20121129A1 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
AR073978A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4-humano
PE20171512A1 (es) Anticuerpos anti-fap
SG10201807877TA (en) Hybrid immunoglobulin containing non-peptidyl linkage
EA200970250A1 (ru) Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
EA200870538A1 (ru) Лиофилизированные композиции анти-egfr антител
RU2010131179A (ru) Жидкая композиция, содержащая антитело высокой концентрации
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
PE20141162A1 (es) Anticuerpos anti-il-23
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
NZ610734A (en) Human antibodies to the glucagon receptor
PE20130206A1 (es) Anticuerpos multivalentes antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
TN2014000120A1 (en) Cd27l antigen binding proteins
PE20141413A1 (es) Formulaciones de anticuerpo y metodos

Legal Events

Date Code Title Description
FD Application declared void or lapsed